The top news stories from the Middle East

Provided by AGP

Got News to Share?

The Middle East Gazette: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Gazette.

Press releases published on May 20, 2026

TRIP CONCIERGE VOTED WORLD’S BEST TRAVEL AGENCY BY IGTP AT 2026 GUILD AWARDS
Studio KHORA’s G House Receives AIA Recognition for Sculptural Waterfront Design
Simeoni Arti Grafiche Becomes World’s First to Acquire the New Scodix Ultra 7000 SHD Press
BPX Launches Affordable RPA Solutions to Help Mid-Market Businesses Automate Operations
Solustiq Emerges as Turkey's First Vertical AI Company Built for the Global Travel Industry
NQUBATOR Successfully Hosts PropTech  Demo Day Hosted by Dubai CommerCity Showcasing the Future of Real Estate
YRC Study: Stock Leakage Drains 3 to 7% of Annual Revenue from Jewelry Retailers, Internal Pilferage the Silent Killer
SA Fab Releases Editorial Guide Exploring the Revival of Indian Hand Block Printed Fashion
DPM Metals Reports New High-Grade Intercepts from the Chelopech Wedge Zone Deep Prospect; Expects Mineral Resource Estimate by Year-End 2026
Azimut Continues to Expand the Fortin Antimony-Gold Zone, Wabamisk Property, James Bay Region, Québec
Azimut poursuit l’expansion de la Zone Fortin (Antimoine-Or) Propriété Wabamisk, région de la Baie James, Québec
مجموعة الخطوط الجوية القطرية تسجل أداءً ماليّاً قوياً رغم التحديات والظروف الاقتصادية العالمية
Qatar Airways Group delivers robust financial performance despite global economic instability
Le groupe Qatar Airways affiche de solides résultats financiers malgré l'instabilité économique mondiale
STARTRADER CEO Peter Karsten Delivers "AI Starter" Keynote at University of Adelaide
SERB Pharmaceuticals erwirbt von Hansa Biopharma europäische und MENA-Rechte an Idefirix® (Imlifidase) für 115 Mio. €
SERB Pharmaceuticals acquiert auprès de Hansa Biopharma les droits européens et MENA d’Idefirix® (imlifidase) pour 115 millions d’euros
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

Share us

on your social networks:

Sign up for:

The Middle East Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.